HSP90 inhibitors have been successfully assessed across a wide range of preclinical/clinical cancers, including gliomas [31], breast cancer [32], lung cancer [33], prostate cancer [34], and colorectal cancer [35]. This evidence concerns the gene HSP90AB1 and prostate cancer.